Bioline RX News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.05.20	BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine (PR Newswire)
05.11.19	BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Mic... (PR Newswire)
31.10.19	BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019 (PR Newswire)
29.10.19	BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019 (PR Newswire)
03.09.19	BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors (PR Newswire)
07.05.19	BioLineRx to Report First Quarter 2019 Results on May 14, 2019 (PR Newswire)
07.05.19	BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors (PR Newswire)
02.01.19	BioLineRx to Present at the 2019 Biotech Showcase (PR Newswire)
06.12.18	BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York (PR Newswire)
08.11.18	BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update (PR Newswire)
01.11.18	BioLineRx to Report Third Quarter 2018 Results on November 8, 2018 (PR Newswire)
22.10.18	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch (RTTNews)
20.10.18	BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress (PR Newswire)
19.10.18	BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress (PR Newswire)
16.10.18	Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED...) (RTTNews)
04.10.18	VTVT Abuzz, TRVN Faces FDA Panel Next Week, BLRX Awaits Data In Oct. (RTTNews)
03.10.18	BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications (PR Newswire)
30.08.18	BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York (PR Newswire)
07.08.18	BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization (PR Newswire)
04.08.18	Week Ahead In Pharmaceuticals - 10 Stocks To Watch (ALNY, INSM, PRTK...) (RTTNews)
01.08.18	BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors (PR Newswire)
30.07.18	BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer (PR Newswire)
18.06.18	BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients (PR Newswire)
13.06.18	BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference (PR Newswire)
22.05.18	BioLineRx Reports First Quarter 2018 Financial Results (PR Newswire)
17.05.18	BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation (PR Newswire)
16.04.18	Better Homes and Gardens Real Estate Enters Australia and New Zealand Through Strategic Relationship as it Celebrates its Ten Year Anniversary (PR Newswire)
26.03.18	BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors (PR Newswire)
14.03.18	BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference (PR Newswire)
06.03.18	BioLineRx Reports Year End 2017 Financial Results (PR Newswire)
27.02.18	BioLineRx to Report Annual 2017 Results on March 6, 2018 (PR Newswire)
06.02.18	BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13 (PR Newswire)
17.01.18	BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer (PR Newswire)
02.01.18	KDMN And 10 Other Biotech Stocks You Should Watch This Month (RTTNews)
05.12.17	BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY (PR Newswire)
21.11.17	BioLineRx Reports Third Quarter 2017 Financial Results (PR Newswire)
19.09.17	Phoenix Ancient Art and Hicham Aboutaam Will Be Exhibiting at Pad London Art + Design Fair (PR Newswire)
07.09.17	BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York (PR Newswire)
23.08.17	Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA... (RTTNews)
21.08.17	BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization (PR Newswire)
08.08.17	BioLineRx Reports Second Quarter 2017 Financial Results (PR Newswire)
02.08.17	BioLineRx to Report Second Quarter 2017 Results on August 8, 2017 (PR Newswire)
01.08.17	Technical Reports on Biotech Equities -- BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix (PR Newswire)
26.07.17	BioLineRx Announces Additional Investment From BVF Partners L.P. (PR Newswire)
10.07.17	BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration (PR Newswire)
06.06.17	Biotech Stock Performance Review -- Cellect Biotechnology, BioDelivery Sciences, BioLine Rx, and Benitec Biopharma (PR Newswire)
01.06.17	BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors (PR Newswire)
25.05.17	BioLineRx Reports First Quarter 2017 Financial Results (PR Newswire)
22.05.17	BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML (PR Newswire)
16.05.17	BioLineRx to Report First Quarter 2017 Results on May 25, 2017 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.03	1.73 %	K V
Part Grp Hldg	1’319.00	1.54 %	K V
Roche Hldg G	270.60	1.39 %	K V
Givaudan	3’913.00	0.80 %	K V
Lonza Grp	561.60	0.72 %	K V
CieFinRichemont	140.35	-0.43 %	K V
Geberit	502.40	-0.67 %	K V
Zurich Insur Gr	540.60	-1.21 %	K V
Swiss Re	132.85	-1.45 %	K V
Kuehne+Nagel Int	201.10	-3.04 %	K V

Nachrichten zu Bioline RX Ltd. (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten